Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery

Area of Science:

• Pharmacology
• Biomaterials Science
• Gastroenterology

Background:

• Chronic inflammatory bowel diseases (IBDs) require improved therapeutic strategies.
• Current treatments for IBDs often suffer from systemic side effects or poor selectivity.
• Localized drug delivery to the colon offers a promising approach to enhance efficacy and minimize adverse effects.

Purpose of the Study:

• To develop and evaluate a novel colon-specific drug delivery system for mesalazine using a macromolecular carrier.
• To utilize azoreductase enzyme activity in the colon for targeted drug release.
• To assess the efficacy of the mesalazine-PEG conjugate in preclinical models of colitis.

Main Methods:

• Synthesis and characterization of three mesalazine-poly(ethylene glycol) (PEG) conjugates with an azo linker.
• In vitro evaluation using mouse colonic epithelial cells (CMT-9).
• In vivo assessment in mice with induced colitis, monitoring body weight, histology, and interleukin-2 beta levels.

Main Results:

• The PEGylated mesalazine conjugate prevented premature drug release in the upper intestine.
• The azo linker facilitated targeted mesalazine release in the colon.
• In vivo studies showed significant improvement in body weight gain, tissue histology, and reduced inflammation markers compared to controls.

Conclusions:

• The developed mesalazine-PEG conjugate represents an effective colon-targeted drug delivery system for IBD treatment.
• This approach enhances therapeutic efficacy by ensuring localized drug action in the colon.
• Targeted delivery minimizes systemic exposure, potentially leading to improved patient outcomes.